Matches 1 - 50 out of 156 1 2 3 4 >
Match Document Document Title
EP1935431A2 Cancer treatments by using a combination of an antibody against her2 and interleukin-2  
Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one...
7371371 Interleukin-2 mutants with reduced toxicity  
Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular...
7364870 MK2 interacting proteins  
The present invention relates to uses of proteins that bind MK2 to modulate inflammation. More particularly, the invention relates to uses of proteins that bind MK2 for treating condition that are...
7357925 Method for treating disorders and diseases treatable with human fibroblast interferon  
PEG-IFN-β conjugates, where a PEG moiety is covalently bound to Cys 17 of human IFN-β, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A...
EP1908477A2 Combination of temozolomide and pegylated interferon-alpha for treating cancer  
A method for treating a human patient afflicted with cancer, comprising administering therapeutically effective amounts of temozolomide and pegylated interferon alpha to such a patient.
7351855 Chemically defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
EP1880736A1 Releasable linkage and composition containing same  
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
EP1878441A2 Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b  
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an...
EP0862455B1 INTERFERON-POLYMER CONJUGATES AND PROCESS FOR PREPARING THE SAME  
Abstract not available
7307148 Method for purification of albumin conjugates  
The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto...
7303760 Method for treating multi-drug resistant tumors  
Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug...
7297676 Thymosin alpha 1 peptide/polymer conjugates  
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of...
7285622 Releasable linkage and compositions containing same  
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
7285526 Interferon antagonists useful for the treatment of interferon related diseases  
The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and/or an abnormal responsivity to, interferon. Alzheimer's...
EP1844815A1 Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers  
Methods of treating a human subject for a cancer characterized by neoplastic B cell growth are provided. The methods comprise administering combination antibody therapy to the subject, where an...
7276248 Conjugate having a cleavable linkage for use in a liposome  
Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by...
EP1834671A2 A method for generation of antibodies to cell surface molecules  
The present invention relates to a method of generating antibodies directed against cell surface antigens and it uses recombinant insect cells as immunogens. The insect cells have been transfected...
7238368 Releasable linkage and compositions containing same  
A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the...
EP1790726A2 Modified and stabilized GDF propeptides and uses thereof  
Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the...
7214366 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules  
Water soluble activated polymers are provided containing an active ethyl sulfone moiety having a reactive site located at the second carbon from the sulfone group. In an embodiment, a poly(ethylene...
7201897 Interferon conjugates  
Physiologically active PEG-IFNα conjugate having a formula as follows:
7186810 Modified peptides as therapeutic agents  
The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention,...
7176256 Biocompatible crosslinked composition  
Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups....
7151135 Crosslinked polymer compositions  
Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple...
7118743 Bispecific molecules cross-linking ITIM and ITAM for therapy  
The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides...
7115581 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
7112337 Liposome composition for delivery of nucleic acid  
A liposome composition for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a lipid that is neutral in charge at physiologic pH and...
7090835 N-terminally chemically modified protein compositions and methods  
Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and...
7056713 Urate oxidase  
The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are...
6989147 Truncated soluble tumor necrosis factor type-I and type-II receptors  
Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor...
6984396 Conjugate having a cleavable linkage for use in a liposome  
Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by...
6969400 Synthetic implant with nonimmunogenicity coating  
Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple...
6956027 N-terminally chemically modified protein compositions and methods  
Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and...
6951939 Multivalent platform molecules comprising high molecular weight polyethylene oxide  
Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their...
6946296 Methods and compositions for polypeptide engineering  
Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are...
6924264 Modified exendins and exendin agonists  
Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages...
6923966 Melanoma therapy  
Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective...
6911496 Composition for administration of a biologically active compound  
Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple...
6894025 Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety  
A poly(ethylene glycol) derivative is disclosed that is activated with a sulfone moiety for selective attachment to thiol moieties on molecules and surfaces. The activated PEG is water soluble,...
6864350 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution  
PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small...
6849270 Releasable linkage and compositions containing same  
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
6833408 Methods for tissue repair using adhesive materials  
A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having...
6800735 Interferon-beta fusion proteins and uses  
A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety;...
EP1055685B1 Non-antigenic branched polymer conjugates  
Abstract of EP1055685 Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides...
6783965 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates  
A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by...
6710169 Adheson variants  
Novel derivatives of cell surface proteins which are homologous to the immunoglobulin superfamily (adhesons) are provided. Amino acid sequence variations are introduced into adheson, the most...
6653072 Methods and compositions for polypeptide engineering  
Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are...
6638500 Polyol-IFN-βconjugates modified at Cys-17 and composition containing same  
PEG-IFN-β conjugates, where a PEG moiety is covalently bound to Cys 17 of human IFN-β, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A...
6613514 Methods and compositions for polypeptide engineering  
Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are...
6605299 Releasable linkage and compositions containing same  
A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
Matches 1 - 50 out of 156 1 2 3 4 >